Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 19/20 | 0.66 |
| ▸ | CDK1 | P06493 | 19/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 19/20 | 0.66 |
| ▸ | CCNB3 | Q8WWL7 | 19/20 | 0.66 |
| ▸ | GSK3B | P49841 | 16/20 | 0.66 |
| ▸ | CDK5 | Q00535 | 14/20 | 0.66 |
| ▸ | CDK5R1 | Q15078 | 14/20 | 0.66 |
| ▸ | GSK3A | P49840 | 13/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912855 | 0.81 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL490933 | 0.81 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778531 | 0.79 | CCNB2 (0.58) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778612 | 0.77 | CCNB2 (0.60) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1779111 | 0.77 | GSK3B (0.63) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778382 | 0.75 | GSK3B (0.60) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778663 | 0.73 | CCNB2 (0.58) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778115 | 0.73 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1777116 | 0.70 | GSK3B (0.68) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778217 | 0.70 | CCNB2 (0.54) | CCNB2CDK1CCNB1CCNB3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| CN-1665809-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | claimed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1263759-B1 | AZAINDOLES | AVENTIS PHARMA LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| CN-100509811-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| CN-100379734-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2008-04-09 | — | — | CN | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| CN-1615873-A | Azaindoles compound | AVENTIS PHARMA LTD (GB) | 2005-05-18 | — | — | CN | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | CCNB2 194/4885CDK1 8/4885CCNB1 218/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | CCNB2 381/4885CDK1 5/4885CCNB1 285/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | CCNB2 244/4885CDK1 13/4885CCNB1 275/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | CCNB2 1015/4885CDK1 37/4885CCNB1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.